Navigation Links
Heptares Augments Business Development Capabilities in Japan and Other Asian Territories
Date:5/24/2013

WELWYN GARDEN CITY, England and BOSTON, May 24, 2013 /PRNewswire/ --

Heptares Therapeutics, the leading GPCR drug discovery and development company, is pleased to announce that it has engaged Mr Akira Usui as a Consultant to augment the Company's business development capabilities in Japan and other Asian territories.

Mr Usui has more than 15 years of experience in business development, licensing and alliance management in the pharmaceutical industry including senior roles at Perlegen Sciences, Inc., Roche Pharma (Japan), Nippon Roche and Tanabe Seiyaku Co. Ltd. Mr Usui is President of Ray Life Sciences Inc., which he established in 2007 to provide business and corporate development consulting services to pharma and biotech companies, universities and venture capital firms with a specific focus on the Japanese market.

Barry Kenny , Heptares' Chief Business Officer, said: "Akira has an exceptional depth of experience in business development and an impressive track record in implementing agreements across multiple international territories. In addition to our existing partnership with Takeda, we are developing significant interest from pharmaceutical companies in Japan in what Heptares' technology can offer. We look forward to working with Akira, who will provide additional support in this region, to manage and advance these multiple new business opportunities for our unique GPCR-focused drug discovery and development capabilities."  

Mr Usui added: "Heptares has established itself as the leader in GPCR-focused drug discovery and has achieved significant milestones both with its partners and in building its own pipeline of drug candidates. Its platform and approach has the potential to unlock the GPCR space to drug discovery and enable the development of new and better targeted medicines for diseases with few effective treatments. I am delighted to work with the Company as it seeks to increase its business development activities in Japan and Asia."

 

About Heptares Therapeutics

Heptares creates new medicines targeting clinically important, yet historically challenging, GPCRs (G protein-coupled receptors), a superfamily of drug receptors linked to a wide range of human diseases. Leveraging our advanced structure-based drug design technology platform, we have built an exciting discovery and development pipeline of novel drug candidates, which have the potential to transform the treatment of serious diseases, including Alzheimer's disease, Parkinson's disease, schizophrenia, migraine and diabetes. Our pharmaceutical partners include Shire, Cubist, Takeda, MorphoSys, AstraZeneca and MedImmune, and we are backed by MVM Life Science Partners, Clarus Ventures, Novartis Venture Fund and Takeda Ventures. To learn more about Heptares, please visit http://www.heptares.com.


'/>"/>
SOURCE Heptares Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Heptares and UK Medical Research Council Extend GPCR Collaboration
2. Heptares to Present at 5th CNS Partnering and Deal-Making Conference (13-14 SEPTEMBER)
3. Heptares to Present at the 6th Annual European Life Sciences CEO Forum (5-6 March)
4. Heptares to Present at Boston Biotech BD and Future Leaders in the Biotech Industry Conferences
5. Generex Augments Antigen Express Scientific Advisory Board
6. Lower Operating Expense Augments Digital X-rays Uptake Across Industries, Finds Frost & Sullivan
7. Pharmaceutical Industry Service Company Awarded The UKs Most Prestigious Business Accolade in Recognition of Outstanding Achievement in International Trade
8. CareFusion to Sell Neurodiagnostic Business to Natus Medical for $58 Million
9. Nominations Open for San Francisco Business Times Health Care Heroes Awards
10. Bayer Employees Named Rising Stars by Healthcare Businesswomens Association
11. Amendia, Inc. and Medline Industries, Inc. Announce Investment and Strategic Business Alliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Key Pharma News Issue 52" report to their offering. ... need in influenza treatment creates a favourable commercial environment for ... and growing patient base that will serve to drive considerable ... flu vaccine would serve to cap sales considerably, but development ...
(Date:6/23/2016)... June 23, 2016 Revolutionary technology ... Oticon , industry leaders in advanced audiology and ... Oticon Opn ™, the world,s first internet connected ... for IoT devices.      (Photo: http://photos.prnewswire.com/prnh/20160622/382240 ... a number of ,world firsts,: , TwinLink™ ...
Breaking Medicine Technology:
(Date:6/26/2016)... Michigan (PRWEB) , ... June 26, 2016 , ... On ... as sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table in Battle ... honor of the city’s history as home to some of the world’s leading providers ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... health policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, ... work on several important health care topics including advance care planning, healthcare costs ...
(Date:6/25/2016)... Long Beach, CA (PRWEB) , ... June 25, 2016 , ... ... from UCLA with Magna Cum Laude and his M.D from the David Geffen School ... San Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at ...
(Date:6/24/2016)... ... 2016 , ... Those who have experienced traumatic events may suffer from a ... such as drug or alcohol abuse, as a coping mechanism. To avoid this pain ... following a traumatic event. , Trauma sufferers tend to feel a range of emotions, ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... ... is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is ...
Breaking Medicine News(10 mins):